
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is projected to achieve a revenue of $250M in Q4 of 2027, which may be challenging, but the launch of new products and increased sales of existing ones will contribute to this growth. The recent J-Code approval for IOPIDINE is expected to improve revenue and address a recognized complication in eye procedures. Risks typical to a biotech company exist, but Harrow is focused on meeting their revenue target through continued growth and strategic acquisitions.
Bears say
Harrow is facing some immediate challenges, including a decline in revenue due to high deductible healthcare plans and a gross-to-net problem, but believes these issues will be resolved in the future. In the meantime, their recent expansion of salesforce and upcoming launch of new products like prefilled syringes and a permanent J code for Iopidine may provide some short-term revenue growth. However, there are risks associated with being in the highly competitive and unpredictable pharmaceutical industry.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares